Natera Dividends and Buybacks

Dividend criteria checks 0/6

Natera does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-0.08%

Buyback Yield

Total Shareholder Yield	-0.08%
Future Dividend Yield	0%
Dividend Growth	n/a
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Payout ratio	n/a

Recent dividend and buyback updates

No updates

Recent updates

Why Natera Remains A 'Hold' For Me Despite Surging MRD Growth And Fatter Margins

Nov 30

Optimistic Investors Push Natera, Inc. (NASDAQ:NTRA) Shares Up 25% But Growth Is Lacking

Aug 31

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if NTRA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NTRA's dividend payments have been increasing.

Dividend Yield vs Market

Natera Dividend Yield vs Market

How does NTRA dividend yield compare to the market?
Segment	Dividend Yield
Company (NTRA)	n/a
Market Bottom 25% (US)	1.4%
Market Top 25% (US)	4.4%
Industry Average (Biotechs)	2.4%
Analyst forecast (NTRA) (up to 3 years)	0%

Notable Dividend: Unable to evaluate NTRA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NTRA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate NTRA's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as NTRA has not reported any payouts.

Discover strong dividend paying companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/12/28 01:37
End of Day Share Price	2025/12/26 00:00
Earnings	2025/09/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Natera, Inc. is covered by 30 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Catherine Ramsey Schulte	Baird
Luke Sergott	Barclays
Raymond Myers	Benchmark Company

Natera Dividends and Buybacks

Dividend criteria checks 0/6

Key information

Recent dividend and buyback updates

Recent updates

Independent Director recently sold US$11m worth of stock

Natera, Inc. Announces Publication of Signatera Analysis from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study in Colorectal Cancer

President of Clinical Diagnostics notifies of intention to sell stock

Natera, Inc. and Alliance Foundation Trials, LLC Announces Initial Translational Research Results from the International Randomized Phase III PALLAS Study

CEO & Director notifies of intention to sell stock

Natera, Inc. Announces New Data on Signatera™ to Be Presented at the 2025 American Society of Hematology Annual Meeting

Why Natera Remains A 'Hold' For Me Despite Surging MRD Growth And Fatter Margins

Lead Independent Director recently sold US$18m worth of stock

Independent Director notifies of intention to sell stock

Now 21% undervalued

No longer forecast to breakeven

Price target increased by 9.9% to US$213

Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Natera, Inc. Raises Earnings Guidance for 2025

CEO & Director notifies of intention to sell stock

Natera, Inc. Announces Expansion to 20 Genes for its Fetal Focus Single-Gene NIPT

Natera, Inc. to Report Q3, 2025 Results on Nov 06, 2025

Natera, Inc. Reports Strong Advanced Adenoma Data from Prospective Processed-Crc Trial, Demonstrating 22.5% Sensitivity and 91.5% Specificity

Natera, Inc. Announces Results from the Randomized, Double-Blind, Phase 3 Imvigor011 Clinical Trial in Muscle-Invasive Bladder Cancer (MIBC)

CEO & Director notifies of intention to sell stock

Natera, Inc. Announces Enrollment Tops 1,600 in Natera's Expands Trial of Single Gene NIPT

Natera, Inc. Announces the Publication of A New Study in the Journal of Clinical Oncology Precision Oncology Precision OnCology

Co-Founder & Director notifies of intention to sell stock

Optimistic Investors Push Natera, Inc. (NASDAQ:NTRA) Shares Up 25% But Growth Is Lacking

Natera, Inc. Announces the Activation of the NRG Oncology Trial, Archer

Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation

Natera, Inc. Announces Positive Topline Results from the Randomized, Phase III IMvigor011 Clinical Trial in Muscle-Invasive Bladder Cancer

Consensus estimates of losses per share improve by 11%

Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Natera, Inc. Raises Earnings Guidance for 2025

Natera, Inc. Launches Fetal Focus A Noninvasive Prenatal Test for Inherited Conditions

Natera, Inc. to Report Q2, 2025 Results on Aug 07, 2025

Natera, Inc. Announces Launch of ABCSG 61, a Randomized Controlled Trial of Signatera™? in Early-Stage Breast Cancer

Natera, Inc. Announces PEDAL Study Successful, Shows Monitoring with Prospera Kidney Provides Accurate Prognosis of Long-Term Clinical Outcomes Following Rejection; Now Published in Journal of Transplantation

Natera Presents Data At ESMO GI on its Tissue-Free Latitude™ MRD

Natera to Present Clinical and Economic Utility of Signatera At Esmo Gi, Highlights Innovations in Mrd

Now 24% undervalued

Natera, Inc.(NasdaqGS:NTRA) dropped from Russell 2500 Index

Forecast to breakeven in 2027

Co-Founder & Director notifies of intention to sell stock

Natera, Inc. Announces Medicare Coverage for Signatera Genome

CEO & Director notifies of intention to sell stock

Natera, Inc. Announces Results from A Large-Scale Pan-Cancer Study of Its Signatera Genome Assay

There's Reason For Concern Over Natera, Inc.'s (NASDAQ:NTRA) Price

Signatera, Prospera And Renasight Will Transform Diagnostics

New minor risk - Profitability

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Natera, Inc. Provides Earnings Guidance for the Year 2025

Natera, Inc. Announces to Present Multiple Datasets in Breast Cancer Together with its Collaborators at 2025 ESMO Breast Cancer Annual Congress in Munich, Germany

Natera, Inc. Announces the American Journal of Transplantation Publishes New Study Evaluating the Performance of Prospera Heart with Dqs to Detect Allograft Rejection

Natera, Inc. Announces Results of Study Led by Stanford University School of Medicine for the Evaluation of Signatera

CEO & Director notifies of intention to sell stock

Natera, Inc. to Report Q1, 2025 Results on May 08, 2025

Natera, Inc. Announces the Results of Its Define-HT Clinical Trial in Heart Transplantation

Natera Announces Broad Clinical Launch of Ultra-S sensitive Signatera Genome MRD Test

Natera, Inc. to Present Data from 8 Studies at 2025 AACR Annual Meeting

CEO & Director exercised options and sold US$2.6m worth of stock

Is Natera, Inc. (NASDAQ:NTRA) Trading At A 23% Discount?

Now 22% undervalued after recent price drop

Natera, Inc., Annual General Meeting, Apr 29, 2025

Co-Founder & Director notifies of intention to sell stock

Co-Founder & Executive Chairman recently sold US$7.4m worth of stock

Natera: Solid Execution, Pricey Stock

Co-Founder & Executive Chairman notifies of intention to sell stock

Natera, Inc. Appoints Monica Bertagnolli as A Member of the Board

Natera, Inc. Announces Enrollment of First Patients in the HEROES Clinical Trial in Metastatic HER2+ Breast Cancer

Now 22% undervalued after recent price drop

Consensus EPS estimates fall by 67%, revenue upgraded

Forecast breakeven date pushed back to 2027

Natera, Inc. Provides Earnings Guidance for the Year 2025

Natera Announces Medicare Coverage of Signatera Test for Surveillance in Lung Cancer

Natera, Inc. to Report Q4, 2024 Results on Feb 27, 2025

Natera, Inc. Strengthens Guidance on ctDNA in Colon Cancer, Rectal Cancer, and Merkel Cell Carcinoma

Natera, Inc. Announces Successful Readout of Randomized, Phase III CALGB (Alliance) / SWOG 80702 Clinical Trial in Colorectal Cancer

Natera to Present New Data at the 2025 ASCO GI Symposium